RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

01 Mar 2023 07:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

27 Feb 2023 08:45:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

23 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

05 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

07 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference

01 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

21 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

08 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update

08 Nov 2022 07:00:04 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

07 Nov 2022 16:01:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®

03 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023

02 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

01 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022

25 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022

12 Oct 2022 08:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

06 Oct 2022 16:02:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)

23 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering

19 Sep 2022 16:01:00 By Nasdaq GlobeNewswire